Led by the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) of the Ministry of Economic Affairs (MOEA), an international exchange initiative for Taiwan’s biotechnology industry took place at BioJapan 2026 in Yokohama, Japan, from October 7 to 9, 2026. Bringing together 17 biotech enterprises, research institutions, and industry organizations, the Taiwan delegation focused on key sectors including drug development, CDMO, cell therapy, and biologics. Through the Taiwan Pavilion and international business partnering sessions, the delegation showcased Taiwan’s innovative capabilities and strong potential for global collaboration.
As part of the Taiwan biotech delegation, LAUNXP Biomedical Co., Ltd. joined domestic industry partners to participate in this international platform, presenting its R&D pipeline and strategic layout in innovative drug development to Japan and the global biotechnology community.
During the event, LAUNXP highlighted its R&D programs, particularly LXP103 and LXP107. Through exhibition showcases and business partnering meetings, the company actively connected with Japanese and international pharmaceutical, biotechnology, and strategic partners to continuously expand global collaboration opportunities.
BIOJAPAN 2026 HIGHLIGHTS
Innovative Pipeline – Highlighting LXP103 and LXP107 to demonstrate LAUNXP’s strategic R&D layout in innovative drug discovery.
Global Partnership – Engaging with Japanese and international biotech and pharmaceutical partners to explore joint R&D, licensing, and strategic collaboration opportunities.
Japan Market Presence – Building upon LAUNXP’s established foundation in Japan to further deepen market presence and drive Asian drug development partnerships.
Media Coverage
During BioJapan 2026, Taiwan’s biotech expansion into Japan garnered widespread industry media attention, with reports highlighting LAUNXP Biomedical’s exhibition presence and strategic development in the Japanese market.
Global Bio & Investment Monthly ｜ 2026.10.07
BioJapan Celebrates 40th Anniversary! Nearly 40 Taiwanese Biotech Enterprises Head to Japan, Showcasing Cross-Border Opportunities in CDMO and Cell Therapy
→ Read Full Article
https://news.gbimonthly.com/tw/article/show.php?num=90591&range=news
LIFE / Precision Medicine Network ｜ 2026.10.07
Taiwanese Firms Target the Japanese Biotech Market: 17 Enterprises Debut at BioJapan 2026, Eyeing CDMO and Cell Therapy Opportunities
→ Read Full Article
PR Newswire ｜ Related Media Coverage
BPIPO Leads 17 Taiwanese Biotech Companies and Research Institutes at BioJapan 2026, Focusing on High-Growth Sectors Such as CDMO, Cell Therapy, and Biologics to Drive Cross-Border Collaboration and Market Expansion via the Taiwan Pavilion and Bilateral Business Partnering.
→ Read Full Article
